Relevant criteria for selecting an intravenous immunoglobulin preparation for clinical use

BioDrugs

Volumn 24, Issue 4, 2010, Pages 211-223

  Chérin, Patrick ^a   Cabane, Jean ^b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b HÔPITAL SAINT ANTOINE   (France)

Author keywords

Blood; Immunodeficiency disorders; Immunoglobulins, general; Immunological disorders; Immunomodulators, general; Inflammation

Indexed keywords

CARIMUNE; FLEBOGAMMADIF; HUMAN IMMUNOGLOBULIN; IG VENA; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULINE IV; INTRATECT; NANOGAM; UNCLASSIFIED DRUG; VIGAM; SODIUM;

ACUTE KIDNEY FAILURE; ANAPHYLAXIS; ASEPTIC MENINGITIS; BACKACHE; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL TRIAL; CONTINUOUS INFUSION; DISEASE SEVERITY; DRUG ACTIVITY; DRUG EFFICACY; DRUG FEVER; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG MANUFACTURE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FLUSHING; GUILLAIN BARRE SYNDROME; HEART INFARCTION; HEMOLYSIS; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE DEFICIENCY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOMODULATION; INFECTION; LUNG INFECTION; MOTOR NEUROPATHY; MUCOCUTANEOUS LYMPH NODE SYNDROME; MYALGIA; NAUSEA; OSMOLARITY AND OSMOLALITY; PRIORITY JOURNAL; REVIEW; RIGOR; RISK BENEFIT ANALYSIS; RISK REDUCTION; SIDE EFFECT; STROKE; VENOUS THROMBOEMBOLISM; VIRUS TRANSMISSION; VOMITING; DOSE RESPONSE; FEMALE; IMMUNE SYSTEM DISEASES; INFLAMMATION; MALE; OSMOLARITY;

DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNE SYSTEM DISEASES; IMMUNOGLOBULINS, INTRAVENOUS; INFLAMMATION; MALE; OSMOLAR CONCENTRATION; SODIUM;

EID: 77954566531     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.2165/11537660-000000000-00000     Document Type: Review

References (103)

1. Ballow M. Safety of IGIV therapy and infusion-related adverse events. Immunol Res 2007; 38 (1-3): 122-132
2. Carbone J. Adverse reactions and pathogen safety of intravenous immunoglobulin. Curr Drug Saf 2007; 1 (1): 9-18
3. Eibl MM. History of immunoglobulin replacement. Immunol Allergy Clin North Am 2008; 28 (4): 737-764
4. Hartung H-P. Advances in the understanding of the mechanism of action of IVIg. J Neurol 2008; 255 Suppl. 3: 3-6
5. Hooper JA. Intravenous immunoglobulins: evolution of commercial IVIG preparations. Immunol Allergy Clin North Am 2008; 28 (4): 765-778
6. Gelfland EW. Critical decisions in selecting an intravenous immunoglobulin product. J Infus Nurs 2005; 28 (6): 366-374
7. Orange JS,Hossny EM, Weiler CR, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immmunology. J Allergy Clin Immunol 2006; 117 (4 Suppl.): S525-53
8. ZLB Behring LLC. Immune globulin intravenous (human) Carimune® NF nanofiltered, lyophilized preparation: US prescribing information. Kankanee (IL): ZLB Behring LLC, 2005
9. Grifols Biologicals Inc. Flebogamma® 5% DIF immune globulin intravenous (human): US prescribing information. Los Angeles (CA):Grifols Biologicals Inc., 2006
10. Baxter Healthcare Corporation. Gammagard S/D [immune globulin intravenous (human)] solvent detergent treated IgA less than 1 mg/mL in a 5% solution: US prescribing information. Westlake Village (CA): Baxter Healthcare Corporation, 2007
11. Baxter Healthcare Corporation. Gammagard S/D immune globulin intravenous (human) IgA less than 2.2 mg/mL, in a 5%solution:US prescribing information. Westlake Village (CA): Baxter Healthcare Corporation, 2008
12. Baxter Healthcare Corporation. Gammagard liquid [immune globulin intravenous (human)] 10%: US prescribing information. Westlake Village (CA): Baxter Healthcare Corporation, 2005
13. Talecris Biotherapeutics Inc. Gamunex® 10% liquid preparation immune globulin intravenous (human), 10% caprylate/chromatography purified: US prescribing information. Triangle Park (NC): Talecris Biotherapeutics Inc., 2008
14. Octapharma USA Inc. Octagam [immune globulin intravenous (human)] 5% liquid preparation: US prescribing information. Hoboken (NJ): Octapharma USA Inc., 2008
15. CSL Behring LLC. Immune globulin intravenous (human) 10% liquid. Privigen®: US prescribing information. Kankakee (IL): CSL Behring LLC, 2007
16. Novartis Pharmaceuticals Corporation. Immune globulin intravenous (human) Sandoglobulin®: US prescribing information. East Hanover (NJ): Novartis Pharmaceuticals Corporation, 2000
17. GrifolsUKLtd. Flebogamma® 5%solution for infusion: summary of product characteristics. Cambridgeshire: Grifols UK Ltd, 2008
18. European Medicines Agency. Summary of product characteristics: Flebogammadif. 2009 [online]. Available from URL: http://www.emea.europa.eu/ humandocs/Humans/EPAR/flebogammadif/flebogammadif.htm [Accessed 2009 Sep 4]
19. Kedrion SpA. IG Vena N IV: summary of product characteristics. Barga, Lucca: Kedrion SpA, 2001
20. Sanquin. Immunoglobuline IV: summary of product characteristics. Amsterdam: Sanquin, 2007
21. Biotest Pharma GmbH. Intratect 50 g/L, solution for infusion: summary of product characteristics. Dreieich: Biotest Pharma GmbH, 2007
22. European Medicines Agency. Kiovig 100 mg/mL solution for infusion: summary of product characteristics. 2006 [online]. Available from URL: http://www.ema.europa.eu/humandocs/Humans/EPAR/kiovig/kiovig.htm [Accessed 2009 Sep 17]
23. Sanquin. Nanogam 50 mg/mL solution for infusion: summary of product characteristics [in Dutch]. Amsterdam: Sanquin, 2009
24. Octapharma Ltd. Normal intravenous immunoglobulin: Octagam® 50 mg/mL solution for infusion. Summary of product characteristics. Coventry: Octapharma Ltd, 2005
25. Octapharma Ltd. Human normal immunoglobulin for intravenous administration (IVIg) Octagam 10%: Octagam 100 mg/mL. Summary of product characteristics. Coventry: Octapharma Ltd, 2008
26. European Medicines Agency. Privigen 100 mg/mL solution for infusion: summary of product characteristics. 2008 [online]. Available from URL: http://www.ema.europa.eu/humandocs/PDFs/EPAR/privigen/emea-com bined-h831en.pdf [Accessed 2009 Sep 17]
27. European Medicines Agency. Assessment report for Privigen. 2008 [online]. Available from URL: http://www.ema.europa.eu/humandocs/ PDFs/EPAR/privigen/H- 831-en6.pdf [Accessed 2009 Sep 17]
28. CSL Behring UK Limited. Sandoglobulin NF liquid, 120 mg/mL solution for infusion. Haywards Heath: CSL Behring UK Limited, 2008
29. HAS (Haute Autorite de Sante). Tegeline 50 mg/mL, poudre et solvant pour solution pour perfusion. 2007 [online]. Available from URL: http://www. has-sante.fr/portail/upload/docs/application/pdf/ct-4164-tegeline-.pdf [Accessed 2010 May 3]
30. BPL (Bio Products Laboratory). Vigam® liquid:UKprescribing information. Elstree: BPL, 2004
31. Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis [see comment]. N Engl J Med 1993 Dec 30; 329 (27): 1993-2000
32. Cherin P, Herson S, Wechsler B, et al. Intravenous immunoglobulin for polymyositis and dermatomyositis. Lancet 1990; 336: 116
33. Cherin P, Herson S, Wechsler B, et al. Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients. Am J Med 1991 Aug; 91 (2): 162-168
34. Cherin P, Pelletier S, Teixeira A, et al. Results and long-term follow-up of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. ArthritisRheum2002; 46: 467-474
35. Dalakas MC, Koffman B, Fujii M, et al. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 2001 Feb 13; 56 (3): 323-327
36. Cherin P, Pelletier S, Teixeira A, et al. Intravenous immunoglobulin for dysphagia of inclusion body myositis. Neurology 2002 Jan 22; 58 (2): 326-327
37. Shah S. Pharmacy considerations for the use of IGIV therapy. Am J Health Syst Pharm 2005; 62 (16 Suppl. 3): S5-11
38. Looney RJ, Huggins J. Use of intravenous immunoglobulin G (IVIG). Best Pract Res Clin Haematol 2006; 19 (1): 3-25
39. Donofrio PD, Berger A, Brannagan 3rd TH, et al. Consensus statement: the use of intravenous immunoglobulin in the treatment of neuromuscular conditions report of the AANEM ad hoc committee. Muscle Nerve 2009 Nov; 40 (5): 890-900
40. Nydegger UE, Sturzenegger M. Adverse effects of intravenous immunoglobulin therapy. Drug Saf 1999; 21 (3): 171-185
41. Welles CC, Tanbra S, Lafayette RA. Hemoglobinuria and acute kidney injury requiring hemodialysis following intravenous immunoglobulin infusion. Am J Kidney Dis 2010; 55 (1): 148-151
42. European Medicines Agency. European Public Assessment Report. Procedural steps taken and scientific information after the authorisation: Flebogammadif. 2009 [online]. Available from URL: http://www.emea.europa.eu/humandocs/ Humans/EPAR/flebogammadif/flebogammadif.htm [Accessed 2009 Sep 4]
43. IPOPI. IPOPI global immunoglobulin list 2009 [online]. Available from URL: http://www.ipopi.org/documents/global-immunoglobulin-list/Ig%20 Global%20list%202008-1112.htm [Accessed 2009 Jul 24]
44. Shah SR. A newer immunoglobulin intravenous (IGIV)-Gammagard liquid 10%: evaluation of efficacy, safety, tolerability and impact on patient care. Expert Opin Biol Ther 2008; 8 (6): 799-804
45. European Medicines Agency. Flebogammadif 50 mg/mL solution for infusion: summary of product characteristics. 2009 [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/flebogamma dif/emea-combined- h781en.pdf [Accessed 2009 Sep 3]
46. Biotest Pharma GmbH. Intratect® product profile. 2009 [online]. Available from URL: http://www.biotest.de/ww/en/pub/plasmaproteins/immunoglo bulins/intratect/product-profile.cfm [Accessed 2009 Sep 17]
47. European Medicines Agency. Kiovig scientific discussion document. 2006 [online]. Available from URL: http://www.emea.europa.eu/humandocs/ PDFs/EPAR/kiovig/062806en6.pdf [Accessed 2009 Sep 17]
48. Terpstra FG, Parkkinen J, Tolo H, et al. Viral safety of Nanogam®, a new 15nm-filtered liquid immunoglobulin product. Vox Sang 2006; 90: 21-32
49. CSL Behring. Manufacturing: partitioning/fractionation. 2009 [online]. Available from URL: http://www.cslbehring.com/s1/cs/enco/1196562782846/con tent/1196562782347/content.htm [Accessed 2009 Sep 23]
50. LFB Biomedicaments. Tegeline 50 mg/mL powder and solvent for solution for infusion: summary of product characteristics. Courtaboeuf: LFB Biomedicaments, 2009
51. Martinez V, Cohen P, Pagnoux C, et al. Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients. Arthritis Rheum 2008 Jan; 58 (1): 308-317
52. Godeau B, Caulier M-T, Decuypere L, et al. Intravenous immunoglobulin for adults with autoimmune thrombocytopenic purpura: results of a randomized trial comparing 0.5 and 1 g/kg b.w. Br J Haematol 1999; 107: 716-719
53. BPL (Bio Products Laboratory). Therapy area-immunoglobulins. 2009 [online]. Available from URL: http://www.bpl.co.uk/public/therapy-areas/ immunoglobulins/normal2.asp [Accessed 2009 Sep 21]
54. More J. Characterization and formulation development of a new liquid intravenous immunoglobulin: Vigam Liquid. Paper presented at the first Plasma Products Biotechnology meeting; Queensland, Australia: March 27- 30, 1999. Downstream 2000; 31: 22-33 [online]. Available from URL: http:// www.gelifesciences.com/aptrix/upp00919.nsf/Content/50DD4C3FFD5A7070 C1257628001CDDF7/$file/18114075.pdf [Accessed 2010 May 25]
55. Kratz A, Lewandrowski KB. Case records of the Massachusetts General Hospital: normal reference laboratory values. N Engl J Med 1998; 339 (15): 1063-1072
56. Skvaril F, Gardi A. Differences among available immunoglobulin preparations for intravenous use. Pediatr Infect Dis J 1988; 7 (5): S43-8
57. Ballow M. Clinical and investigational considerations for the use of IGIV therapy. Am J Health Syst Pharm 2005; 62 (16 Suppl. 3): S12-8
58. Martin TD. IGIV: contents, properties, and methods of industrial production- evolving closer to a more physiologic product. Int Immunopharmacol 2006; 6 (4): 517-522
59. Wassermann RL, Church JA, PeterHH, et al. Pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiency. Eur J Pharm Sci 2009; 37: 272-278
60. Siegel J. The product: all intravenous immunoglobulins are not equivalent. Pharmacotherapy 2005; 25 (11 Pt 2): 78S-84S
61. Stiehm ER. Lessons fromKawasaki disease: all brands of IVIG are not equal. J Pediatr 2006; 148 (1): 6-8
62. Elluru S, Van Huyen J-PD, Bayry J, et al. Comparative study of the antiinflammatory effect of two intravenous immunoglobulin preparations manufactured by different processes [published erratum appears in Immunol Lett 2006 Nov; 107 (2): 182]. Immunol Lett 2006; 107 (1): 58-62
63. Kaveri SV, Lacroix-Desmazes S, Bayry J. The antiinflammatory IgG. N Engl J Med 2008 Jul 17; 359 (3): 307-309
64. Lux A, Aschermann S, Biburger M, et al. The pro and anti-inflammatory activities of immunoglobulin G. Ann Rheum Dis 2010 Jan; 69 Suppl. 1: i92-6
65. Crow AR, Brinc D, Lazarus AH. New insight into the mechanismof action of IVIg: the role of dendritic cells. J Thromb Haemost 2009 Jul; 7 Suppl. 1: 245-248
66. Grillo JA, Gorson KC, Ropper AH, et al. Rapid infusion of intravenous immune globulin in patients with neuromuscular disorders.Neurology 2001; 57: 1699-1701
67. Shah S, Vervan M. Use of IV immune globulin and occurrence of associated acute renal failure and thrombosis. Am J Health-Sys Pharm 2005; 62: 720-725
68. Vo AA, Cam V, Toyoda M, et al. Safety and adverse events profiles of intravenous gammaglobulin products used for immunomodulation: a singlecenter experience. Clin J Am Soc Nephrol 2006; 1: 844-852
69. KazatchkineM. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345 (10): 747-755
70. Lemm G. Composition and properties of IVIg preparations that affect tolerability and therapeutic efficacy. Neurology 2002; 59 Suppl.: S28-32
71. Wiles CM, Brown P, Chapel H, et al. Intravenous immunoglobulin in neurological disease: a specialist review. J Neurol Neurosurg Psychiatry 2002; 72: 440-448
72. Cunningham-Rundles C, Zhou Z, Mankarious S, et al. Long-term use of IgAdepleted intravenous immunoglobulin in immunodeficient subjects with anti-IgA antibodies. J Clin Immunol 1993; 13: 272-278
73. Martin TD. Safety and tolerability of intravenous immunoglobulins. Electroenceph Clin Neurophysiol Suppl 1999; 50: 514-520
74. Berger M, Pinciaro PJ, for the Flebogamma 5%Investigators. Safety, efficacy and pharmacokinetics of Flebogamma 5% [immune globulin intravenous (human)] for replacement therapy in primary immunodeficiency disease. J Clin Immunol 2004; 24 (4): 389-396
75. Church JA, Leibl H, Stein MR, group eaTU-P-I-S. Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IGIV 10%] in patients with primary immunodeficiency. J Clin Immunol 2006; 26 (4): 388-395
76. Ochs HD, Pinciaro PJ, Octagam Study G. Octagam 5%, an intravenous IgG product, is efficacious and well tolerated in subjects with primary immunodeficiency diseases. J Clin Immunol 2004 May; 24 (3): 309-314
77. Godeau B, Lesage S,Divine M, et al. Treatment of adult chronic autoimmune thrombocytopenic purpura with repeated high-dose intravenous immunoglobulin. Blood 1993 Sep 1; 82 (5): 1415-1421
78. Colovic M, Dimitrijevic M, Sonnenburg C, et al. Clinical efficacy and safety of a novel intravenous immunoglobulin preparation in adult chronic ITP. Hematol J 2003; 4 (5): 358-362
79. Varga G, Volkova Z, LeiblH, et al. Efficacy and safety of the new intravenous immunoglobulin IGIV 10% in adults with chronic idiopathic thrombocytopenic purpura. Transfus Med Hemother 2006 Dec; 33 (6): 509-514
80. ZhangG, Lopez PHH, SheikhKA. Comparison of different brands of IVIg in an in vitro model of immune neuropathy. J Neuroimmunol 2006; 173 (1-2): 200-203
81. Roifman CM, Schroeder H, Berger M, et al. Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency: a randomized double-blind trial. Int Immunopharmacol 2003 Sep; 3 (9): 1325-1333
82. Bussel JB, Eldor A, Kelton JG, et al. IGIV-C, a novel intravenous immunoglobulin: evaluation of safety, efficacy, mechanisms of action, and impact on quality of life. Thromb Haemost 2004 Apr; 91 (4): 771-778
83. Wolf HH, Davies SV, Borte M, et al. Efficacy, tolerability, safety and pharmacokinetics of a nanofiltered intravenous immunoglobulin: studies in patients with immune thrombocytopenic purpura and primary immunodeficiencies. Vox Sang 2003 Jan; 84 (1): 45-53
84. Tsai MH, Huang YC, Yen MH, et al. Clinical responses of patients with Kawasaki disease to different brands of intravenous immunoglobulin [see comment]. J Pediatr 2006 Jan; 148 (1): 38-43
85. Rosenfeld EA, Shulman ST, Corydon KE, et al. Comparative safety and efficacy of two immune globulin products in Kawasaki disease. J Pediatr 1995 Jun; 126 (6): 1000-1003
86. Debes A, Bauer M, Kremer S. Tolerability and safety of the intravenous immunoglobulin Octagam: a 10-year prospective observational study. Pharmacoepidemiol Drug Saf 2007 Sep; 16 (9): 1038-1047
87. Bussel JB,Hanna K, The IGIV-C in ITP Study Group. Safety and tolerability of a novel chromatography-based intravenous immunoglobulin when administered at a high infusion rate in patients with immune thrombocytopenic purpura. Am J Hematol 2007; 82: 192-198
88. Hamrock DJ. Adverse events associated with intravenous immunoglobulin therapy. Int Immunopharmacol 2006; 6 (4): 535-542
89. Brennan VM, Salome-Bentley NJ, Chapel HM, Immunology Nurses Study. Prospective audit of adverse reactions occurring in 459 primary antibodydeficient patients receiving intravenous immunoglobulin. Clin Exp Immunol 2003 Aug; 133 (2): 247-251
90. Pierce LR, Jain N. Risks associated with the use of intravenous immunoglobulin. Transfus Med Rev 2003 Oct; 17 (4): 241-251
91. Bonilla FA. Intravenous immunoglobulin: adverse reactions and management. J Allergy Clin Immunol 2008 Dec; 122 (6): 1238-1239
92. Robak T, Mainau C, Pyringer B, et al. Efficacy and safety of a new intravenous immunoglobulin 10% formulation (Octagam®10%) in patients with immune thrombocytopenia. Hematology. In press
93. Katz U, Kishner I,Maglashvili D, et al. Long term safety of IVIG therapy in multiple sclerosis: 10 years experience. Autoimmunity 2006; 39 (6): 513-517
94. Daw Z, Padmore R, Neurath D, et al. Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysis. Transfusion 2008 Aug; 48 (8): 1598-1601
95. Rodriguez-Baez G, Lin RY. Intravenous immunoglobulin-associated renal failure reported between 2004-2008 [abstract no. 515]. J Allergy Clin Immunol 2010; 125 (2 Suppl. 1): AB131
96. Canadian Blood Services. Important information regarding IVIG-associated hemolysis. 2009 [online]. Available from URL: http://www.bloodservices. ca/CentreApps/Internet/UW-V502-MainEngine.nsf/resources/Customer Letters09/$file/CL-2009-02.pdf [Accessed 2009 Sep 4]
97. Robak T, SalamaA, Kovaleva L, et al. Efficacy and safety of Privigen, a novel liquid intravenous immunoglobulin formulation, in adolescent and adult patients with chronic immune thrombocytopenic purpura. Hematology 2009; 14 (4): 227-236
98. Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with highdose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med 1994; 121: 259-262
99. Siegel J. Safety considerations in IGIV utilization. Int Immunopharmacol 2006; 6 (4): 523-527
100. Reid B, Van Allen D, LaGrange CA, et al. Protocol recommendations for administration of intravenous immunoglobulin in Canada. J Infus Nurs 2006; 29 (3): 158-164
101. Paran D, Herishanu Y, Elkayam O, et al. Venous and arterial thrombosis following administration of intravenous immunoglobulins. Blood Coagul Fibrinolysis 2005; 16: 313-316
102. Dalakas MC. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology 1994 Feb 01; 44: 223-226
103. CSL Behring Canada Ltd. Sandoglobulin® NF Liquid immune globulin intravenous (human) 12% solution for infusion: Canadian product monograph. Ottawa (ON): CSL Behring Canada Ltd, 2007